Any Grade >/= hemorrhage or bleeding event within  days of Day  of Cycle 
Any grade >/= hemorrhage or bleeding event within  weeks prior to initiation of study treatment
Any hemorrhage or bleeding event ? grade  within  weeks.
Any Grade >= hemorrhage or bleeding event within  days of Day  of Cycle 
Grade ?  hemorrhage or bleeding event within  days prior to initiation of study treatment
FOR ALL PHASES (Ib AND II): Patients with evidence or history of bleeding diathesis; any hemorrhage or bleeding event >= CTCAE grade  within  weeks of start of study medication
Patients with evidence or history of bleeding diathesis; any hemorrhage or bleeding event >= CTCAE grade  within  weeks before the start of study treatment
Patients with evidence or history of bleeding diathesis; any hemorrhage or bleeding event >= CTCAE grade  within  weeks of start of study enrollment
Contraindication to antiangiogenic agents, including:\r\n* Serious non-healing wound, non-healing ulcer, or bone fracture\r\n* Major surgical procedure or significant traumatic injury within  weeks prior to initiating study treatment\r\n* Pulmonary hemorrhage/bleeding event >= grade  (Common Terminology Criteria for Adverse Events [CTCAE] v.) within  weeks prior to initiating study treatment\r\n* Any other hemorrhage/bleeding event >= grade  (CTCAE v.) within  weeks prior to initiating study treatment
Contraindication to antiangiogenic agents, including:\r\n* Serious non-healing wound, non-healing ulcer, or bone fracture\r\n* Major surgical procedure or significant traumatic injury within  weeks prior to initiating study treatment\r\n* Pulmonary hemorrhage/bleeding event >= grade  within  weeks prior to initiating study treatment\r\n* Any other hemorrhage/bleeding event >= grade  within  weeks prior to initiating study treatment
Contraindication to antiangiogenic agents, including:\r\n* Bronchopulmonary hemorrhage/bleeding event >= grade  (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version .) within  weeks or less prior to first dose of study drug\r\n* Any other hemorrhage/bleeding event >= grade  (CTCAE version [v].) within  weeks or less prior to first dose of study treatment\r\n* Radiological evidence of any intracranial hemorrhage within the  weeks or less prior to first dose of study treatment \r\n* History of significant intratumoral, intracerebral, or subarachnoid hemorrhage\r\n* Serious non-healing wound, ulcer, or bone fracture\r\n* Documented bowel perforation within  months of the start of study treatment
Any other hemorrhage/bleeding event >= CTCAE grade  within  weeks of first dose of study drug
Grade  or higher bleeding event =<  months prior to randomization
Any hemorrhage / bleeding event ? CTCAE v.. Grade  within  weeks before randomization
Patients who have a history or current evidence of bleeding disorder, i.e., any hemorrhage/bleeding event of CTCAE grade >= , =<  days prior to registration
Contraindication to antiangiogenic agents, including:\r\n* Serious non-healing wound, non-healing ulcer, or bone fracture\r\n* Major surgical procedure or significant traumatic injury within  weeks prior to initiating study treatment; other surgical procedures within  weeks prior to initiating study treatment\r\n* Pulmonary hemorrhage/bleeding event >= grade  within  weeks prior to initiating study treatment\r\n* Any other hemorrhage/bleeding event >= grade  within  weeks prior to initiating study treatment
Patients with evidence or history of bleeding diathesis; any hemorrhage or bleeding event >= CTCAE grade  within  weeks prior to registration
Any hemorrhage or bleeding event >= grade  within  weeks prior to prior to registration
Pulmonary hemorrhage/bleeding event >= CTCAE grade  within  weeks of first-dose of study drug
Any other hemorrhage/bleeding event >= CTCAE grade  within  weeks of first dose of study drug
Patients with any pulmonary hemorrhage/bleeding event grade  or higher within  weeks before randomization
Have experienced a Grade ? bleeding event within  months (? months) prior to randomization.
Pulmonary hemorrhage/bleeding event >= CTCAE grade  within  weeks of study registration
Any other hemorrhage/bleeding event >= CTCAE grade  within  weeks of study registration
Pulmonary hemorrhage/bleeding event > or equal to CTCAE v grade  within  weeks of first dose of study drug
Any other hemorrhage/bleeding event > or equal to CTCAE v grade  within  weeks of first dose of study drug
Evidence or history of bleeding diathesis or any hemorrhage or bleeding event > CTCAE grade  =<  weeks prior to randomization
Evidence or history of tendency or predisposition to active bleeding. Any hemorrhage or bleeding event of Grade  or higher within  weeks of start of study medication;
Pulmonary hemorrhage/bleeding event >= CTCAE grade  within  weeks of first dose of study drug
Any other hemorrhage/bleeding event >= CTCAE grade  within  weeks of first dose of study drug
Evidence or history of bleeding diathesis; any hemorrhage or bleeding event >= grade  within  weeks of start of FOLFIRI
CTCAE version . > grade  pulmonary hemorrhage or > grade  of other forms of bleeding within  days prior to enrollment.
Contraindication to antiangiogenic agents, including: \r\n* Pulmonary hemorrhage/bleeding event >= grade  within  weeks of first dose of study drug\r\n* Any other hemorrhage/bleeding event >= grade  within  weeks of first dose of study treatment\r\n* Serious non-healing wound, ulcer, or bone fracture
Subjects who have a history of, or current evidence of bleeding disorder, i.e. any hemorrhage / bleeding event of CTCAE Grade >=  < weeks before the first dose of study drug.
Any hemorrhage or bleeding event
Pulmonary hemorrhage/bleeding event >= CTCAE grade  within  weeks of first dose of study drug
Any other hemorrhage/bleeding event >= CTCAE grade  within  weeks of first dose of study drug
Pulmonary hemorrhage/bleeding event > CTCAE grade  within  weeks of study entry
Any other hemorrhage/bleeding event > CTCAE grade  within  weeks of study entry
Any other hemorrhage or bleeding of Grade ? within  days prior to first dose of study treatment
Evidence or history of bleeding disorder, i.e. any hemorrhage / bleeding event of > Grade  within  weeks prior to the first dose of study drug
Any hemorrhage or bleeding event >= grade  within  weeks prior to registration
Pulmonary hemorrhage/bleeding event >= CTCAE v . grade  within  weeks of first dose of study drug
Any other hemorrhage/bleeding event >= CTCAE v . grade  within  weeks of first dose of study drug
Has experienced a Grade ?  bleeding event within  months prior to randomization
Any other hemorrhage/bleeding event >= CTCAE grade  within  weeks of first dose of study drug
Any other hemorrhage/bleeding event >= CTCAE Grade  within  weeks of first dose of study drug
